Short Interest in Cardiff Oncology, Inc. (NASDAQ:CRDF) Expands By 7.2%

Cardiff Oncology, Inc. (NASDAQ:CRDF) saw a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 7,320,000 shares, an increase of 7.2% from the September 30th total of 6,830,000 shares. Based on an average daily volume of 495,200 shares, the short-interest ratio is presently 14.8 days.

Analysts Set New Price Targets

Separately, Craig Hallum began coverage on shares of Cardiff Oncology in a report on Friday, September 6th. They issued a “buy” rating and a $8.00 price target for the company.

Institutional Trading of Cardiff Oncology

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Callan Capital LLC grew its stake in Cardiff Oncology by 37.2% in the first quarter. Callan Capital LLC now owns 42,747 shares of the company’s stock valued at $228,000 after purchasing an additional 11,600 shares in the last quarter. Blair William & Co. IL grew its stake in shares of Cardiff Oncology by 32.4% in the first quarter. Blair William & Co. IL now owns 172,180 shares of the company’s stock valued at $919,000 after buying an additional 42,180 shares in the last quarter. Vanguard Group Inc. increased its holdings in Cardiff Oncology by 0.5% during the first quarter. Vanguard Group Inc. now owns 1,921,257 shares of the company’s stock worth $10,260,000 after buying an additional 9,468 shares during the last quarter. Assenagon Asset Management S.A. raised its position in Cardiff Oncology by 380.6% during the second quarter. Assenagon Asset Management S.A. now owns 1,215,922 shares of the company’s stock worth $2,699,000 after acquiring an additional 962,940 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in Cardiff Oncology in the second quarter valued at $256,000. Institutional investors and hedge funds own 16.29% of the company’s stock.

Cardiff Oncology Trading Up 2.9 %

Shares of NASDAQ:CRDF traded up $0.09 during trading on Friday, hitting $3.21. 560,838 shares of the company’s stock traded hands, compared to its average volume of 929,799. The company has a 50-day moving average price of $2.59 and a 200-day moving average price of $2.82. Cardiff Oncology has a 52 week low of $0.94 and a 52 week high of $6.42. The company has a market cap of $149.43 million, a price-to-earnings ratio of -3.65 and a beta of 1.96.

Cardiff Oncology (NASDAQ:CRDF) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.01). Cardiff Oncology had a negative return on equity of 62.65% and a negative net margin of 6,143.91%. The business had revenue of $0.16 million during the quarter, compared to the consensus estimate of $0.12 million. During the same period in the prior year, the firm earned ($0.25) EPS. On average, analysts predict that Cardiff Oncology will post -1 earnings per share for the current fiscal year.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.